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Introduction
Gastric carcinoma still remains one of the most com-
mon alimentary tract malignancies worldwide,
although the last decade has brought a falling tenden-
cy in its incidence and mortality rate [1,2]. The process
of carcinogenesis in the stomach involves a number of
factors, including the family of epidermal growth fac-
tors. Growth factors have been found in both mature
and embryonic tissues. These important regulators of
proliferation and differentiation play a significant role
in the maintenance of epithelial integrity [3]. Physio-
logically, normal epithelial cells secrete growth factors
which regulate cell exchange through autocrine and
paracrine pathways. It is anticipated that these factors
can regulate transition from G2 phase and mitosis of
the cell cycle [4]. It has been demonstrated that ErbB1
(EGFR) and ErbB2 (c-erbB-2/HER-2) are associated
with the development of many carcinomas. Increased
ErbB1 expression has been observed in numerous
types of carcinomas, including breast carcinoma,
glioblastoma, gastric carcinoma and squamous cell
carcinoma (SCC). In certain types of neoplasms,
ErbB1 overexpression is accompanied by intercellular
domain deletion that leads to constitutive activation.
Moreover, ErbB1 activation via the autocrine pathway,
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Abstract: The c-erbB-2 (HER-2/neu), EGF and EGFR (erbB-1) proteins, members of the epidermal growth factor receptor
family, play a role in cell growth by binding to cell membrane receptors. The aim of the current study was to evaluate the
expression of c-erbB-2, EGF and EGFR in advanced gastric carcinoma and to analyze its relationship with chosen anato-
mo-clinical parameters and prognosis. Standard avidin-biotin-peroxidase was used for c-erbB-2, EGF and EGFR immuno-
histochemical staining (Novostain Super ABC Kit Universal); anti-human c-erbB-2 protein monoclonal antibody NCL-c-
erbB-2-316,  anti-Epidermal Growth Factor monoclonal antibody (clone EGF-10) and EGFR goat polyclonal IgG (p-
EGFR).  A statistically significant correlation was found between c-erbB-2, EGF, EGRF expressions in the main mass of
tumor and lymph node metastasis (p=0.000; p=0.000; p=0.00001, respectively). Also an association was observed between
c-erbB-2 expression and Bormann's and Lauren's classifications (p=0.05; p=0.006, respectively). Similarly, the expression
of EGFR in main mass of tumor was correlated with the depth of invasion (p=0.007) and histological differentiation
(p=0.04).  Moreover, the expression of c-erbB-2 in the main mass of tumor and lymph node metastasis was associated with
the age of the patients (p=0.03; p=0.0002 respectively). Strong association was found between the expression of EGRF in
lymph node metastasis and histological differentiation (p=0.04).  Positive expression of c-erbB-2 in lymph node metastasis
was correlated with lymph node involvement (p=0.04). Positive expression of c-erbB-2 in the main mass of tumor and in
lymph node metastasis was strongly correlated with postoperative survival (p=0.00001; p=0.003 respectively). We also
found a relationship between EGF expression in gastric tumor and survival time (p=0.003).  No association was noted
between the expression of EGFR in the main mass of tumor and in lymph node metastasis and between the expression of
EGF in lymph node metastasis and survival time. Our results suggest that the expression of c-erbB-2 and EGF protein can
help predict the postoperative survival time.
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attributed to the correlation with one or more EGF-
dependent ligands, may have a crucial role in neoplas-
tic transformation [5,6]. In the case of breast carcino-
ma, gene c-erbB-2 amplification is a significant index
of early relapse and shorter survival [7]. EGF plays an
important part in the stimulation of epithelial prolifer-
ation, and in differentiation and growth of cells in the
alimentary tract. It accelerates healing of ulcerative
niches and ensures cytoprotection in the stomach. The
EGF is produced in the submandibular salivary glands
and in Brunner's glands in the duodenum. It is capable
of binding to the specific receptor (EGFR) located in
the cell membrane [8]. It has been shown that EGFR
expression increases in gastric carcinoma tissues and
correlates with unfavorable prognosis. EGF exerts an
effect on the growth of carcinoma cells; however, its
role in this process has not been fully elucidated [3].
The human proto-oncogene c-erbB-2 (HER-2) is a
transmembrane glycoprotein showing structural
homology with the epidermal growth factor receptor
(EGFR). In physiological conditions, it affects cell
growth and differentiation [9,10]. The c-erbB-2
expression correlates with the clinico-pathological
stage of the disease and with its relapse in breast car-
cinoma [11], ovarian carcinoma [12] and lung carcino-
ma [13]. It has been revealed that the overexpression
of gene c-erbB-2 and the gene-coded protein in gastric
carcionma correlates with the intestinal-type carcino-
ma [14], lymph node metastases [15], peritoneal
spread [16] and overall survival [17,18].
The present study objective was to assess the
expression of c-erbB-2, EGF and EGFR proteins in
correlation with chosen clinico-pathological parame-
ters and survival time in patients after curative resec-
tion of advanced gastric carcinoma.
Material and methods
Collection of samples. The study group consisted of 55 chosen
patients with advanced gastric carcinoma (17 women and 38 men),
operated on in the years 1996-98. The mean age was 60.4 years
(range 30-78). The patients were clinically monitored for 84
months.
Immunohistochemistry. In all cases, specimens were obtained
from the main mass of tumor and metastatic lymph nodes. They
were fixed in 40g/L formaldehyde, embedded in paraffin and cut
into 5 μm sections. The sections were deparaffinized in three
changes of xylene and hydrated through an alcohol series of a
decreasing concentration. For detection of c-erbB-2 and EGF pro-
teins, the sections were heated to 95°C for 15 min in citrate buffer
(10 mmol/l) and incubated with 0.5% hydrogen peroxide solution
in methanol for 15 min and with monoclonal antibodies c-erbB-2
(NCL-c-erbB-2-316, Novocastra, diluted 1:50) and EGF (clone
EGF-10, Sigma Aldrich, Poland, diluted 1:50) for 1 hour.
Novostain Super ABC Kit (NCL- ABCm, Novocastra Laboratories
Ltd, UK) was applied as a detection kit. In order to detect EGFR
protein expression, the pre-deparaffinized and hydrated sections
were incubated with 3% hydrogen peroxide solution and then with
polyclonal antibody EGFR (p-EGFR, sc:12351, Santa Cruz
Biotechnology, Inc, dilution 1:100) throughout the night at room
temperature. LSAB+HRP Kit (DAKO) was used for detection. The
antigen-antibody complex was visualized by means of DAB chro-
mogen (S3000, DAKO, Poland). After rinsing in distilled water,
the sections were stained with hematoxylin and eosin. After dehy-
dration and mounting on a Canadian balsam, the sections were sub-
jected to histopathological microscopic examination.
Evaluation of samples. Protein expression was assessed using a
semi-quantitative method and defined as follows:
• High expression – when more than 50% of carcionoma cells
were c-erbB-2, EGF and EGRF-positive
• Low expression- when there was no reaction or less than 50%
of cells were c-erbB-2, EGF and EGFR-positive.
At least 500 carcinoma cells in each tissue specimen were
microscopically found to be c-erbB-2, EGF and EGFR-positive
(×400).
Statistical analysis. Statistical analysis was based on test χ2 and
exact Fisher's test. The p<0.05 was considered statistically signifi-
cant. Multivariate Cox regression analysis was done to evaluate the
5-year overall survival.
Results
The study was performed on a group of 55 patients
with advanced gastric carcinoma. The expression of
tumor c-erbB-2 was observed by immunohistochem-
istry in the cell membrane, while EGF and EGFR in
the cytoplasm (Fig. 1,2 and 3, respectively). Statistical
analysis of the c-erbB-2, EGF and EGFR proteins
revealed no association with patients' gender, tumor
location in the main mass of tumor or lymph node
metastasis. No correlation was also found between the
expression of c-erbB-2 and EGF in the main mass of
tumor and depth of invasion or histological differenti-
ation as well as between EGR, EGRF and Bormann's
classification in gastric tumor. Moreover, there was no
association noted between c-erbB-2, EGF, EGFR
expressions in lymph node metastasis and depth of
invasion, Bormann's classification or Lauren's classifi-
cation. We found no correlation between the expres-
sion of c-erbB-2, EGF in lymph node metastasis and
histological differentiation. Similarly, there was no
association found between the expression of EGF and
EGFR in lymph node metastasis and age of patients or
lymph node involvement (Table 1 and 2).
A strong, statistically significant correlation was
found between the expression of c-erbB-2, EGF,
EGFR in the main mass of tumor and lymph node
metastasis (p=0.000; p=0.000; p=0.00001 respective-
ly). Also an association was found between the expres-
sion of c-erbB-2 in gastric tumor and Lauren's classifi-
cation (p=0.006). At the same time, correlation was
observed between c-erbB-2 expression in the main
mass of tumor and Bormann's classification or age of
patients (p=0.05 and p=0.03). High EGFR expression
in the main mass of tumor was associated with depth
of invasion and histological differentiation (p=0.007;
p=0.04 respectively). Borderline results were observed
654 J. Czyzewska et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(4): 654 (653-661) 
10.2478/v10042-009-0120-1
in the main mass of tumor between EGF expression
and age (p=0.06) and between EGFR and Lauren's
classification (p=0.08) (Table 1). Moreover, a strong
correlation was found between c-erbB-2 expression in
lymph node metastasis and lymph node presence
(p=0.04) or age of patients (p=0.0002). Also, high
expression of EGFR in lymph node metastasis was
associated with histological differentiation (p=0.04)
(Table 2).
Similarly, the expression of c-erbB-2 was found to
correlate with positive tumor EGF and EGFR expres-
sions (p=0.0004, p=0.003, respectively) (Tables 3, 4).
Strong association was found between the expression
of c-erbB-2 in the main mass of tumor and c-erbB-2 in
lymph node metastasis (p=0.0002) (Table 5). More-
over, we found a correlation between the expression of
EGF and EGFR in the main mass of tumor and lymph
node metastasis (p=0.0003; p=0.003 respectively)
(Table 7, 8). Positive staining for c-erbB-2 in lymph
node metastasis was associated with EGFR expression
in the main mass of gastric tumor (p=0.05) (Table 6).
As revealed by Cox's analysis, positive expression
of c-erbB-2 in the main mass of tumor  and in lymph
node metastasis was strongly correlated with the over-
all postoperative survival time (p=0.00001; p=0.003)
(Figs. 4,7). The survival of patients with high tumor c-
erbB-2 expression was shorter (35 months) as com-
pared to patients with low c-erbB-2 expression (84
months). Moreover, high mortality rate was observed
in patients with high c-erbB-2 expression after 13-29
months, while in the low-c-erbB-2 expression group
the mortality rate increased after 33 months and 46-60
months (Fig. 4). Also, we found a strong statistical cor-
relation between c-erbB-2 expression in lymph node
metastasis and time of survival (p=0.003) (Fig. 7). The
overall survival in patients with high expression of c-
erbB-2 protein was 35 months, as compared to patients
with low expression of c-erbB-2 – 68 months.
The mean survival time of patients with high tumor
EGF expression was 84 months, as compared to patients
with low expression – 69 months. Increased mortality in
the former group was observed between the 45-60
months after surgery. In the low-expression group, mor-
tality increased after 11-23 months (Fig. 5), which was
statistically significant (p=0.03). There was no signifi-
cant association between EGF expression in lymph node
metastasis and time of survival (data not published).
In our study, the overall postoperative survival time in
high-EGFR expression patients in the main mass of
tumor was 84 months, as compared to low-EGFR expres-
sion patients (67 months) (Fig. 6). Similarly, patients with
high EGFR expression in lymph node metastasis had 
a considerably longer postoperative survival time 
(61 months), compared to those with low-expression in
metastasis (58 months) (data not published). However,
no statistical significance was observed.
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Fig. 1. Membrane cell staining pattern  of c-erbB-2 in primary
tumor.
Fig. 2. Low expression of EGF in neoplastic cells.
Fig. 3. High expression of EGFR in primary tumor.
Discussion
Growth factors constitute the cell transmission path-
way, which plays a significant role in such processes
as proliferation control, cell differentiation, apoptosis
and neoplastic transformation [19,20]. The EGF fami-
ly members exhibit a similar range of biological activ-
ity induced by binding and activation of the EGF
receptor [21]. Although the role of growth factors in
oncogenesis of the alimentary tract diseases has been
recently in the focus of attention, it is still not com-
pletely elucidated [22-24]. In the current study, a low
immunohistochemical reaction to c-erbB-2 was
observed in 78% of cases, mainly in the intestinal-type
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Table1. Expression of c-erbB-2, EGF, EGFR and chosen clinico-pathological parameters in gastric carcinoma.
*NS – non statistical significence
carcinoma according to Lauren, but also in type II and
IV according to Bormann's classification. There was
no correlation of c-erbB-2, EGR, EGFR expression in
gastric carcinoma with gender or location. There was
also no association between the expression of c-erbB-
2, EGF in gastric tumor and depth of invasion or his-
tological differentiation. Moreover, no correlation was
observed between positive staining for EGF and
EGFR in the main mass of tumor and Bormann's clas-
sification, which was in agreement with other authors
[25,26]. Tsigris et al. [28] found no correlation
between c-erbB-2 expression in gastric carcinoma and
histological subtype, differentiation grade, tumor loca-
tion, TNM stage, gastric wall invasion depth and pres-
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Table 2. Expression of c-erbB-2, EGF, EGFR in lymph node metastasis and histological differentiation.
*NS – non statistical significence
ence of lymph node metastases or distant metastases.
Also Yu et al. [29] observed no association between
the expression of c-erbB-2 and age, gender or tumor
differentiation grade in gastric carcinoma patients.
However, according to Orita, c-erbB-2-positive tumors
showed incidence of peritoneal dissemination, liver
metastasis and lymph node involvement, in compari-
son with findings in the c-erbB-2 negative ones [27].
Motojima et al. [30] found a relationship between c-
erbB-2 expression and lymph node metastasis in well-
differentiated gastric adenocarcinomas. The c-erbB-2-
positive tumors metastasized much more frequently
not only to the local lymph nodes but also to distant
sites, as compared to the c-erbB-2 -negative tumors.
The c-erbB-2 as a co-receptor for various stromal
growth factors co-operates with ErbB1 (EGF-receptor)
and neuroregulin receptors (ErbB-3 and ErbB-4).
Showing low expression in normal mature cells, ErbB-
2 is overexpressed in 20-30% of carcinomas of the
breast, stomach, lungs and prostate [31]. At the same
time, Lee et al. [32] found an association between the
expression of c-erbB-2 and gender, Bormann's type,
histological type and Lauren's classification. They also
observed a correlation of borderline significance
between age of patients and expression of c-erbB-2.
Orita H et al. [27] elucidated prognostic signifi-
cance of the expression of c-erbB-2 oncogene in gas-
tric carcinoma patients. They found out that c-erbB-
2 expression was associated with considerably short-
er postoperative survival time. In patients with posi-
tive and negative c-erbB-2 expression, a 5-year sur-
vival reached 29% and 47%, respectively. Similar
results have been reported by some other authors [4,
14, 25]. These data suggest that c-erbB-2 expression
can be a prognostic factor for gastric carcinoma
patients. However, according to other studies, c-
erbB-2 does not exert a significant effect on the
overall survival time in gastric carcinoma patients
[33,34]. We observed a significant correlation
between c-erbB-2 expression in the main mass of
tumor and postoperative survival time of patients
(Fig. 1). Patients with high tumor expression of this
protein had a considerably shorter postoperative sur-
vival time, as compared to the low-expression
patients. These results suggest that c-erbB-2 expres-
sion may function as a prognostic factor for patients
with advanced gastric carcinoma.
EGF acts as a potential mitogen both for normal
and neoplastic cells through interaction with a specif-
ic cell surface receptor. EGF binding leads to phos-
phorylation of tyrosine receptor residue, causing
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Table 3. Expression of c-erbB-2 and EGF in primary tumor of gas-
tric carcinoma.
Table 4. Expression of c-erbB-2 and EGFR in primary tumor of
gastric carcinoma.
Table 5. Expression of c-erbB-2 in main mass of tumor and lymph
node metastasis.
Table 6. Expression of c-erbB-2  in lymph node metastasis and
EGFR in main mass of tumor. 
Table 7. Expression of EGF and EGFR  in main mass of tumor.
Table 8. Expression of EGF and EGFR  in lymph node metastasis.
transduction of the intracellular signal and enhance-
ment of several regulatory cascades associated with
lithogenesis [35]. The expression of EGF receptor or
EGF correlates with unfavorable prognosis in gastric
carcinoma patients [37]. It has been demonstrated
that patients who simultaneously had high expression
of EGFR and TGF-α had much worse prognosis – a
5-year survival time reached 12%. At low concentra-
tion of these two proteins or when only the expres-
sion of EGFR or its ligand was observed, the 5-year
survival increased up to 45% and 36%, respectively
[38]. In our study, the postoperative survival time in
patients with high tumor EGF expression was longer
(approximately 1 year), as compared to patients with
low expression of this protein (Fig. 5). As reported by
some authors, EGF expression in gastric carcinoma
correlates with the depth of invasion in the gastric
wall and with the presence of lymph node metastases,
and indicates "worse" 5-year survival [39]. We found
that high expression of EGF in the main mass of
tumor may predict longer time of postoperative sur-
vival. However, we revealed a strong, statistically
significant relationship between EGF expression and
lymph node involvement.
The first preliminary data concerning the level of
EGFR in the gastric wall were described by Yasiu et
al. [36], indicating an increase in the level of EGFR
in neoplastic tissue compared to normal mucosa.
Similar observations have been reported by other
authors [40,41]. We also found much stronger
immunohistochemical reaction in neoplastic tissue
than in normal tissue (unpublished data). The
increase in EGFR level was associated with clinical
advancement of cancer and with shorter survival
time. The elevated EGFR level was noted especially
in more invasive carcinomas (T3/4), with lymph node
involvement, in advanced carcinomas according to
UICC (III), in low-differentiated cancers, in diffuse-
659Expression of c-erbB-2, EGF, EGFR in gastric cancer
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(4): 659 (653-661) 
10.2478/v10042-009-0120-1
Fig. 4. Correlation of c-erbB-2 protein expression in main mass of
tumor with survival of patients with advanced gastric cancer.
Fig. 6. Correlation of EGFR protein expression in main mass of
tumor with survival of patients with advanced gastric cancer.
Fig. 5. Correlation of EGF protein expression in main mass of
tumor with survival of patients with advanced gastric cancer.
Fig. 7. Correlation of c-erbB-2 protein expression in lymph node
metastasis with survival of patients with advanced gastric cancer.
type carcinomas according to Lauren and those located
far from the cardia. Kopp et al. [40] suggested that in the
case of chronic inflammation or tissue damage the phys-
iological effect of the ligand for the EGF-receptor path-
way, associated with the regulation of regeneration and
healing in the gastric mucosa, may additionally stimu-
late the process of neoplastic transformation in this
mucosa and tumor progression. We observed EGFR
expression in more than 54% of gastric cancers. High
expression was observed mainly in the intestinal type
and poorly differentiated carcinomas, as well as in those
infiltrating the whole gastric wall or at least into the
serosa layer, the results being statistically significant. As
reported by Gamboza-Dominguez et al. [43], lack or
low expression of EGFR protein was significantly cor-
related with prolonged postoperative survival time, as
compared to moderate and strong expression. In the cur-
rent study, survival time in patients with high tumor
EGFR expression was 17 months longer, as compared
to those with low expression (Fig. 6). No correlations
were observed between survival time and EGFR expres-
sion in metastatic lymph nodes (3 months; data not pub-
lished). Thus, it can be assumed that  EGFR expression
in the main mass of tumor in patients with advanced
gastric cancer may indicate a "better" 5-year overall sur-
vival time. However, the results were statistically
insignificant.
A significant correlation was observed between c-
erbB-2 and EGF, and EGFR expression in tumor. Also
EGF expression in the main mass of tumor was associ-
ated with EGFR expression in gastric tumor and EGF
expression in the metastatic lymph node strongly corre-
lated with EGFR expression. Our results may indicate a
relationship between EGF expression and histological
malignancy in the main mass of tumor. The primary
tumor c-erbB-2 expression was most strongly correlat-
ed with survival time, which was longer by 49 months
in the high-expression group, compared to the group
with negative expression. High expression of EGF pro-
tein was observed in moderately-differentiated tumors.
Patients with high tumor EGF expression had longer
survival time than those with low expression (statisti-
cally significant differences). High expression of EGFR
protein was observed in types III and IV according to
Bormann's classification. Postoperative survival time in
patients with high EGFR expression both in the main
tumor mass and in metastatic lymph nodes was consid-
erably longer as compared to low expression (lack of
statistical significance).  Concluding, our results indi-
cate the usefulness of the assessment of c-erbB-2 and
EGF expression in relation to patients' survival. 
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